Chronic Lymphocytic Leukemia

Successful CAR T-cell production was achieved in all 11 patients who underwent apheresis and cell production but were still alive at the time of infusion, according to result presented during the BMT- EHA 4th European CAR T-Cell Meeting.

The FDA will now make a decision on the approval application for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma in June following an ODAC meeting.

Even with the available agents and knowledge of when to select which option, there is an unmet medical need in the chronic lymphocytic leukemia landscape, according to Jennifer R. Brown, MD, PhD.

Data supporting zanubrutinib for the treatment of chronic lymphocytic leukemia or small lymphocytic leukemia will undergo a regular FDA review in consideration for FDA approval.

During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.

During a live virtual event, Javier Pinilla-Ibarz, MD, PhD, discussed treatment options for chronic lymphocytic leukemia including ibrutinib, acalabrutinib, and venetoclax with obinutuzumab.

Jennifer R. Brown, MD, PhD, discusses the patient population of the SEQUOIA trial of zanubrutinib and venetoclax for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Chimeric antigen receptor T-cell therapies have demonstrated potential in chronic lymphocytic leukemia. However, T-cell dysfunction that is inherent to the disease, including reduced proliferative and cytotoxic capacities, limits the efficacy of this approach, according to an expert.

Major clinical trials are looking to answer substantial questions in the treatment of patients with chronic lymphocytic leukemia, according to Matthew Davids, MD, MMSc.

In an interview with Targeted Oncology, Jennifer Brown, MD, PhD discussed the early analysis of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia and deletion 17p.

During a Targeted Oncology live event, John M. Pagel, MD, PhD, and participants discussed their experiences with BTK inhibitors such as acalabrutinib and ibrutinib in terms of efficacy and tolerability as well as other treatment options in patients with chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline treatment options for patients with chronic lymphocytic leukemia, with questions by Targeted Oncology.

John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.

An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.

John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.

A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.

John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.

A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.

John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.

The combination of low-dose acalabrutinib/rituximab showed to be feasible and effective in CLL/SLL.

Acalabrutinib demonstrated a favorable risk-benefit profile in R/R CLL.

Compared with ibrutinib, acalabrutinib demonstrates less toxicity burden In CLL.

Preliminary results from the phase 2 ERADIC trial signal promise for ibrutinib plus venetoclax for the treatment of chronic lymphocytic leukemia.

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.

Increased rates of complete responses with bone marrow undetectable minimal residual disease were seen with the time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia.

While no significant difference in overall survival benefit between the treatment groups was observed, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

Compared to those who received rituximab and bendamustine, elderly patients treated with ibrutinib-containing regimens for chronic lymphocytic leukemia saw a progression-free survival benefit.

The costs of treatment and time spent managing adverse effects varied significantly in patients with chronic lymphocytic leukemia treated with acalabrutinib, ibrutinib, and venetoclax.

Jennifer R. Brown, MD, PhD, discusses the implications of the SEQUOIA trial, which looked at the combination of zanubrutinib and venetoclax for the treatment of patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.